Stay updated on Pembrolizumab with Radium-223 in mCRPC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with Radium-223 in mCRPC Clinical Trial page.

Latest updates to the Pembrolizumab with Radium-223 in mCRPC Clinical Trial page
- CheckyesterdayChange DetectedAdded related topics Prostate cancer and MedlinePlus Genetics and updated the page revision label from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check8 days agoChange DetectedFunding notice and related-topic links were removed from the page; the main study details and trial information remain unchanged.SummaryDifference0.5%

- Check16 days agoChange DetectedAdded related topics links for Prostate cancer and MedlinePlus Genetics, affecting navigation but not study data or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check30 days agoChange DetectedThe page now includes a Results section with primary and secondary outcomes and updated study dates (start, primary completion, study completion) and enrollment. This provides current information about the trial findings and status.SummaryDifference0.4%

- Check44 days agoChange DetectedDeleted a MedlinePlus Genetics topic related to Prostate cancer, removing it from the page's core topics.SummaryDifference0.2%

- Check51 days agoChange DetectedAdded a government-operating-status notice and a version bump to v3.2.0; removed the previous version label v3.1.0.SummaryDifference2%

Stay in the know with updates to Pembrolizumab with Radium-223 in mCRPC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Radium-223 in mCRPC Clinical Trial page.